Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cemiplimab and Quad Shot Radiation in Elderly or Frail Patients With Locally Advanced Cutaneous Squamous Cell Carcinoma of the Head and Neck
NCT07869823Phase 1Recruiting
- Sponsor
- Vanderbilt-Ingram Cancer Center
- Start
- Sep 2026
- Primary completion
- Sep 2028
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of cemiplimab in cutaneous squamous cell carcinoma (cSCC), sponsored by Vanderbilt-Ingram Cancer Center. Primary endpoint: Feasibility of Cemiplimab and Quad Shot Radiation at 1 year. Started Sep 2026; status: recruiting.
02
Drugs
cemiplimab
03
Conditions
cutaneous squamous cell carcinoma (cSCC)
Beyond the preview
Go deeper on NCT07869823.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07869823.